

Special Issue

Potassium Channels as Novel Therapeutic Targets

Message from the Guest Editors

K⁺ channels constitute the largest and most diverse family of ion channels, with almost 80 different genes encoding the principal pore-forming subunits. Recent progress in structural biology, molecular pharmacology, and electrophysiology/in vivo experiments led to a good understanding of the physiological role of many K⁺ channel members and their therapeutic potential. Pharmacological strategies for targeting these channels include venom peptides, antibodies, and small molecules. Modulation can occur in the form of blockers that inhibit the channels or in the form of openers that activate these channels. With their often tissue-defined distribution, they offer tremendous opportunities for the development of new drugs to treat, for example, cardiovascular disorders, neurological diseases, cancer, as well as autoimmune and metabolic diseases. In this Special Issue, we aim to bring together research from experts in the field that highlight therapeutic agents and strategies, and which identify future directions that will lead to novel discoveries and therapies for K⁺-channel-associated diseases.

Guest Editors

Dr. Eva-Maria Zangerl-Plessl

Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Vienna, Austria

Dr. Anna Stary-Weinzinger

Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria

Deadline for manuscript submissions

closed (26 February 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/134399

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)